Ravuconazole Eisai/Bristol-Myers Squibb.
Eisai and Bristol-Myers Squibb (BMS) are developing the triazole, ravuconazole, as a potential treatment for fungal infection [187888]. Eisai selected the compound for further development on the basis of its good safety profile and well-balanced antifungal activity [187888]. Ravuconazole has a broader antifungal spectrum than fluconazole and itraconazole, particularly against strains of Candida krusei and Cryptococcus neoformans [271854], [342757], [370312]. By June 1999, the compound was undergoing phase II trials [327113]. In November 2001, it was reported that BMS was seeking a co-development partner for the compound [430011]. In October 2001, analysts at ABN Amro predicted sales of US $50 million in 2003 [444020].
Arikan
Sevtap
S
Department of Microbiology and Clinical Microbiology, Hacettepe University Medical School, Ankara, Turkey. sarikan@metu.edu.tr
Rex
John H
JH
D000284:Administration, Oral; D000818:Animals; D000935:Antifungal Agents / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D006801:Humans; D009181:Mycoses / Q000188:drug therapy; D013329:Structure-Activity Relationship; D013844:Thiazoles / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology*; D014230:Triazoles / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology*
D000935:Antifungal Agents; D013844:Thiazoles; D014230:Triazoles; C104066:ER 30346